| Muscular Dystrophy |
1 |
1 |
| Muscle |
0 |
0.54 |
| Genomic Medicine |
0 |
0.52 |
| Spinal Muscular Atrophy |
0 |
0.44 |
| Gene Therapy |
0 |
0.43 |
| Biologic Therapy |
0 |
0.42 |
| Skeletal Myoblasts |
0 |
0.38 |
| Dystrophinopathies |
0 |
0.32 |
| Facioscapulohumeral Dystrophy |
0 |
0.32 |
| Hospital |
0 |
0.22 |
| Cardiovascular Imaging |
0 |
0.21 |
| Revenue and Practice Management |
0 |
0.18 |
| Healthcare and Medical Technology |
0 |
0.17 |
| Clinical Research |
0 |
0.16 |
| Genetics |
0 |
0.16 |
| Heart |
0 |
0.16 |
| Genetic Disorders |
0 |
0.15 |
| Genetic Testing |
0 |
0.15 |
| Heart Failure (HF) |
0 |
0.15 |
| Child |
0 |
0.11 |
| Echocardiography |
0 |
0.11 |
| Fatigue |
0 |
0.11 |
| Grant |
0 |
0.11 |
| Magnetic Resonance Imaging |
0 |
0.11 |
| Orphan Drugs |
0 |
0.11 |
| Quality of Life |
0 |
0.11 |
| Rare Diseases |
0 |
0.95 |
| Tissue |
0 |
0.11 |
| Health Insurance |
0 |
0.08 |
| Muscular Atrophy |
0 |
0.07 |